A practical reference on cyclic heptapeptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-03 and is reviewed periodically as new material appears.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Lyophilised cake or flake |
| Solubility class | Soluble in water and aqueous buffer | Also soluble in some polar organic solvents |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Typical analytical method | LC-MS/MS | Reversed-phase separation with mass detection |
| Molecular formula | C50H69N15O9 | Free base; salt forms differ |
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Americium-243, an alpha emitter, has a half-life of 7350 years, the longest of all americium isotopes. It is formed in the nuclear fuel cycle mainly by neutron capture on plutonium-242 followed by beta decay. Production increases exponentially with increasing burnup as a total of 5 neutron captures on 238U are required. If MOX-fuel is used, particularly MOX-fuel high in 241Pu and 242Pu, more americium overall and more 243Am will be produced. It decays by either emitting an alpha particle (decay energy 5.439 MeV) to become 239Np, which then quickly goes to 239Pu, or, very rarely, spontaneous fission. The fission rate is about 60% that of americium-241 or about 0.7/g/s. As for the other americium isotopes, and more generally for all alpha emitters, 243Am is carcinogenic in case of internal contamination after being inhaled or ingested. 243Am also presents a risk of external irradiation associated with the gamma ray emitted by its short-lived decay product 239Np. The external irradiation risk for the other two americium isotopes (241Am and 242mAm) is less than 10% of that for americium-243.
There are several different secondary messenger systems (cAMP system, phosphoinositol system, and arachidonic acid system), but they all are quite similar in overall mechanism, although the substances involved and overall effects can vary. In most cases, a ligand binds to a cell surface receptor. The binding of a ligand to the receptor causes a conformation change in the receptor. This conformation change can affect the activity of the receptor and result in the production of active second messengers. In the case of G protein-coupled receptors, the conformation change exposes a binding site for a G-protein. The G-protein (named for the GDP and GTP molecules that bind to it) is bound to the inner membrane of the cell and consists of three subunits: alpha, beta and gamma. The G-protein is known as the "transducer." When the G-protein binds with the receptor, it becomes able to exchange a GDP (guanosine diphosphate) molecule on its alpha subunit for a GTP (guanosine triphosphate) molecule. Once this exchange takes place, the alpha subunit of the G-protein transducer breaks free from the beta and gamma subunits, all parts remaining membrane-bound. The alpha subunit, now free to move along the inner membrane, eventually contacts another cell surface receptor - the "primary effector." The primary effector then has an action, which creates a signal that can diffuse within the cell. This signal is called the "second (or secondary) messenger." The secondary messenger may then activate a "secondary effector" whose effects depend on the particular secondary messenger system.
== Subsets == The Russell 1000 Index can be subdivided into the mega-cap Russell Top 200 Index (with about 200 constituents) and the Russell Midcap Index (with about 800 constituents). As of April 30, 2025, the Russell Top 200 and Russell Midcap comprised about 78% and 22%, respectively, of the Russell 1000's total market cap. Other subsets of the Russell 1000 (all classified within the mega-cap segment) include:
Various enzymes or transporters involved in vasodilation are differentially expressed in those with pulmonary arterial hypertension. PAH is associated with reduced prostacyclin synthase activity in the vascular smooth muscle cells, resulting in decreased prostacyclin (PGI2) levels (prostacyclin acts as a vasodilator and inhibitor of vascular smooth muscle proliferation). The vasoconstrictor and cell proliferation activator endothelin-1 is also more active in those with PAH. And those with PAH also have evidence of reduce Nitric oxide synthetase activity, resulting in lower levels of the vasodilator nitric oxide. And those with PAH also more commonly express the L-allelic variant of the 5-HTT gene promoter, resulting in increased expression of the serotonin transporter (5-HTT), and leading to vasoconstriction via pulmonary artery smooth muscle proliferation.
Sources: en.wikipedia.org
== Activists == Samuel Cutler Ward (1831), lobbyist known as the "King of the Lobby" Henry Bergh* (1834), founder of the American Society for the Prevention of Cruelty to Animals and the Massachusetts Society for the Prevention of Cruelty to Children Arthur B. Spingarn (1897), civil rights activist; elected president of the National Association for the Advancement of Colored People 1940–1965; namesake of the Moorland–Spingarn Research Center at Howard University George Marshall (1926), political activist and conservationist John B. Trevor Jr. (1931), director and treasurer of the Pioneer Fund David Crook (1935), British-born Communist ideologue, activist, spy, husband of Isabel Crook, professor at Beijing Foreign Studies University Robert Gnaizda (1957), lawyer, activist, and co-founder of advocacy group Greenlining Institute Morris J.
Phlebotomy is the process of making a puncture in a vein, usually in the arm or hand, with a cannula for the purpose of drawing blood. The procedure itself is known as a venipuncture, which is also used for intravenous therapy. A person who performs a phlebotomy is called a phlebotomist, although most doctors, nurses, and other technicians can also carry out a phlebotomy. In contrast, phlebectomy is the removal of a vein. Phlebotomies that are carried out in the treatment of some blood disorders are known as therapeutic phlebotomies. The average volume of whole blood drawn in a therapeutic phlebotomy to an adult is 1 unit (450–500 ml) weekly to once every several months, as needed.
Addition of a 5' cap to the 5' end of the pre-mRNA molecule Addition of a 3' poly(A) tail is added to the 3' end pre-mRNA molecule Removal of introns via RNA splicing The 5' cap is added to the 5' end of the pre-mRNA molecule and is composed of a guanine nucleotide modified through methylation. The purpose of the 5' cap is to prevent break down of mature mRNA molecules before translation, the cap also aids binding of the ribosome to the mRNA to start translation and enables mRNA to be differentiated from other RNAs in the cell. In contrast, the 3' Poly(A) tail is added to the 3' end of the mRNA molecule and is composed of 100–200 adenine bases. These distinct mRNA modifications enable the cell to detect that the full mRNA message is intact if both the 5' cap and 3' tail are present. This modified pre-mRNA molecule then undergoes the process of RNA splicing. Genes are composed of a series of introns and exons, introns are nucleotide sequences which do not encode a protein while, exons are nucleotide sequences that directly encode a protein. Introns and exons are present in both the underlying DNA sequence and the pre-mRNA molecule, therefore, to produce a mature mRNA molecule encoding a protein, splicing must occur. During splicing, the intervening introns are removed from the pre-mRNA molecule by a multi-protein complex known as a spliceosome (composed of over 150 proteins and RNA). This mature mRNA molecule is then exported into the cytoplasm through nuclear pores in the envelope of the nucleus.
Sources: en.wikipedia.org
Krypton's multiple emission lines make ionized krypton gas discharges appear whitish, which in turn makes krypton-based bulbs useful in photography as a white light source. Krypton is used in some photographic flashes for high speed photography. Krypton gas is also combined with mercury to make luminous signs that glow with a bright greenish-blue light. Krypton is mixed with argon in energy efficient fluorescent lamps, reducing the power consumption, but also reducing the light output and raising the cost. Krypton costs about 100 times as much as argon. Krypton (along with xenon) is also used to fill incandescent lamps to reduce filament evaporation and allow higher operating temperatures. Krypton's white discharge is sometimes used as an artistic effect in gas discharge "neon" tubes. Krypton produces much higher light power than neon in the red spectral line region, and for this reason, red lasers for high-power laser light-shows are often krypton lasers with mirrors that select the red spectral line for laser amplification and emission, rather than the more familiar helium-neon variety, which could not achieve the same multi-watt outputs. The krypton fluoride laser is important in nuclear fusion energy research in confinement experiments. The laser has high beam uniformity, short wavelength, and the spot size can be varied to track an imploding pellet. In experimental particle physics, liquid krypton is used to construct quasi-homogeneous electromagnetic calorimeters.
Most rattlesnake species mate during the summer or fall, while some species mate only in the spring, or during both the spring and fall. Females secrete small amounts of sex pheromones, which leave a trail the males follow using their tongues and Jacobson's organs as guides. Once a receptive female has been located, the male often spends several days following her around (a behavior not common outside of the mating season), frequently touching and rubbing her in an attempt to stimulate her. The males of some species, such as timber rattlesnakes (C. horridus), fight each other during the mating season, in competition over females. These fights, known as "combat dances", consist of the two males intertwining the anterior portion of their bodies, often with their heads and necks held vertically. The larger males usually end up driving the smaller males away. Although many kinds of snakes and other reptiles are oviparous (lay eggs), rattlesnakes are ovoviviparous (give birth to live young after carrying eggs inside). The female produces the ova ("eggs") in her ovaries, after which they pass through her body cavity and into one of her two oviducts. The ova are arranged in a continuous chain in a coiled section of the oviduct, known as the "tuba". Male rattlesnakes have sexual organs known as hemipenes, located in the base of the tail. The hemipenis is retracted inside of the body when mating is not occurring. The hemipenis is similar to the human penis.
codons, resulting in 2078 free parameters. However, the rates for transitions between codons which differ by more than one base are often assumed to be zero, reducing the number of free parameters to only
Because the molecular weight of endotoxins is usually over 10 kD, ultrafiltration can sometimes be used to perform as a size based separation. Due to the high variability of endotoxin size, it can be difficult to select the correct membrane, hence this method is best used only when all endotoxins present are larger than 300,000 Da. Commercially available ultra filters have been shown to remove pyrogens to a level below 0.001 EU/ml.
Sources: en.wikipedia.org
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.
No. Lyophilisation slows degradation rather than stopping it, and the rate depends on residual moisture, temperature and light exposure. Freezer storage extends useful life but does not make the material permanent.
A certificate is only as good as its traceability to a specific batch and a named laboratory. Documents lacking batch numbers, method descriptions or laboratory identifiers carry little weight. Confirming what was actually received generally requires a separate test of the material in hand.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.